ArticleScientific reports2023
Characterization of bacteriophage vB_KleM_KB2 possessing high control ability to pathogenic Klebsiella pneumoniae.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 24 citations in OpenAlex.
- Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Genomic characterization of novel lytic bacteriophages targeting carbapenemase producing multidrug resistant Klebsiella pneumoniae from Ethiopia: a molecular study.BMC microbiology · 2026Article
- Therapeutic and immunomodulatory effects of phage therapy in red hybrid tilapia challenged with Klebsiella pneumoniae.Archives of microbiology · 2026Article
- Isolation and Characterization of aAntibiotics (Basel, Switzerland) · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.Scientific reports · 2026Article
- Characterization of broad host range bacteriophages vKpIN31 and vKpIN32 against hospital-acquired Klebsiella pneumoniae in Dakar, Senegal.Scientific reports · 2025Article
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
- Bacteriophage therapy to combat MDR non-fermenting Gram-negative bacteria causing nosocomial infections: recent progress and challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Characterizations of Newly IsolatedViruses · 2025Article
- Isolation, Characterization, and Anti-Biofilm Activity of a NovelAntibiotics (Basel, Switzerland) · 2025Article
- From Isolation to Application: Utilising Phage-Antibiotic Synergy in Murine Bacteremia Model to Combat Multidrug-Resistant Enterococcus faecalis.Microbial biotechnology · 2025Article
- Article
- Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistantCurrent pharmaceutical design · 2025Review
- Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-ResistantInfection and drug resistance · 2025Review
- Article
- Characterization of Newly Isolated Bacteriophages Targeting Carbapenem-Resistant Klebsiella pneumoniae.Journal of microbiology (Seoul, Korea) · 2024Article
- Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae.Scientific reports · 2024Article
- High activity and specificity of bacteriophage cocktails against carbapenem-resistantFrontiers in microbiology · 2024Article
- Isolation and preliminary characterization of a novel bacteriophage vB_KquU_φKuK6 that infects the multidrug-resistant pathogenFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is a widespread pathogen of several human diseases. The emergence of multidrug-resistant K. pneumoniae makes the treatment of these diseases a significant challenge. The application of bacteriophages is a potential approach for dealing with the emergence of multidrug-resistant pathogenic bacteria. This study isolates a novel bacteriophage vB_KleM_KB2 that infects the multidrug-resistant clinical isolates of K. pneumoniae. The bacteriophage exhibits a short latent period of 10 min, and can effectively lyse the bacterium within 60 min. Notably, the bacteriophage can completely inhibit the growth of the host bacterium at the initial concentration of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.